Lipanthyl Nt (Fenofibrate (Nanonised))

Fenofibrate activates the nuclear receptor peroxisome proliferator‑activated receptor‑α (PPARα). This activation up‑regulates genes that increase fatty‑acid oxidation, enhance lipoprotein lipase activity, and reduce hepatic production of very‑low‑density lipoprotein, leading to lower plasma triglycerides and modest improvements in LDL‑ and HDL‑cholesterol.

The specific dose of Lipanthyl Nt is determined by the prescribing clinician based on the patient’s individual clinical condition, laboratory values, and response to therapy. Dosage may be adjusted according to therapeutic goals and tolerability, and should follow the prescriber’s written instructions.

Safety data for fenofibrate during pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their healthcare provider.

To order Lipanthyl Nt, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team will then provide pricing, availability, shipping details and any necessary import documentation.

The primary alternative to fenofibrate is another fibrate, gemfibrozil, which also lowers triglycerides but has a higher risk of drug‑drug interactions, especially with statins. Compared with statins, fenofibrate is less potent at lowering LDL‑cholesterol but is more effective at reducing triglycerides, making it useful when triglyceride reduction is the primary goal.

Lipanthyl Nt should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Lipanthyl Nt is administered orally, usually once daily with a meal to enhance absorption. Patients should swallow the tablet whole with water and follow any additional instructions provided by their prescriber regarding timing relative to food.

The most serious adverse events associated with fenofibrate include myopathy or rhabdomyolysis (especially when combined with certain statins), severe liver injury, and acute renal failure. Patients should promptly report unexplained muscle pain, weakness, dark urine, jaundice, or sudden changes in kidney function to their healthcare professional.

Lipanthyl Nt is contraindicated in patients with severe hepatic impairment, active gallbladder disease, or known hypersensitivity to fenofibrate or any excipients. Caution is also advised for individuals with moderate renal impairment, uncontrolled hypothyroidism, or a history of gallstones.